Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool, UK.
Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
Pharmacoeconomics. 2024 Nov;42(11):1209-1236. doi: 10.1007/s40273-024-01410-x. Epub 2024 Aug 7.
The disability-adjusted life year (DALY), a key metric for health resource allocation, encompasses morbidity through disability weights. Widely used in tuberculosis cost-effectiveness analysis (CEAs), DALYs play a significant role in informing intervention adopt/reject decisions. This study reviews the values and consistency of disability weights applied in tuberculosis-related CEAs.
We conducted a systematic review using the Tufts CEA database, updated to July 2023 with searches in Embase, Scopus and PubMed. Eligible studies needed to have included a cost-per-DALY ratio, and additionally either evaluated a tuberculosis (TB) intervention or included tuberculosis-related weights. We considered all tuberculosis health states: with/without human immunodeficiency virus (HIV) coinfection, TB treatments and treatment side effects. Data were screened and extracted independently by combinations of two authors.
A total of 105 studies spanning 2002-2023 across 50 countries (mainly low- and middle-income countries) were extracted. Disability weights were sourced primarily from the Global Burden of Disease (GBD; 100/165; 61%), with 17 non-GBD studies additionally referenced, along with primary derivation. Inconsistencies in the utilisation of weights were evident: of the 100 usages of GBD-sourced weights, only in 47 instances (47%) had the weight value been explicitly specified with an appropriate up-to-date reference cited (constituting 28% of all weight usages, 47/165). Sensitivity analyses on weight values had been conducted in 30% of studies (31/105). Twelve studies did not clearly specify weights or their sources; nine further calculated DALYs without morbidity. The review suggests methodological gaps in current approaches for representing important aspects of TB, including TB-HIV coinfection, treatment, drug-resistance, extrapulmonary TB and psychological impacts. We propose a set of best practice recommendations.
There is a need for increased rigour in the application, sensitivity testing and reporting of TB disability weights. Furthermore, there appears a desire among researchers to reflect elements of the tuberculosis experience beyond those allowed for by GBD disability weights.
残疾调整生命年(DALY)是健康资源分配的关键指标,通过残疾权重涵盖发病率。在结核病成本效益分析(CEA)中广泛使用,DALY 在为干预措施的采用/拒绝决策提供信息方面发挥着重要作用。本研究回顾了应用于结核病相关 CEA 的残疾权重的价值和一致性。
我们使用塔夫茨 CEA 数据库进行了系统评价,该数据库更新至 2023 年 7 月,在 Embase、Scopus 和 PubMed 中进行了搜索。符合条件的研究需要包括每 DALY 成本比,并且还需要评估结核病 (TB) 干预措施或包含与结核病相关的权重。我们考虑了所有结核病健康状况:有无人类免疫缺陷病毒 (HIV) 合并感染、TB 治疗和治疗副作用。数据由两名作者的组合独立筛选和提取。
共提取了 2002 年至 2023 年来自 50 个国家(主要是中低收入国家)的 105 项研究。残疾权重主要来自全球疾病负担(GBD;100/165;61%),此外还参考了 17 项非 GBD 研究,以及主要推导。权重使用的不一致性显而易见:在 100 项 GBD 来源权重的使用中,只有在 47 个实例中(47%)明确指定了权重值,并引用了适当的最新参考(占所有权重使用的 28%,47/165)。30%的研究(31/105)对权重值进行了敏感性分析。有 12 项研究没有明确指定权重或其来源;另有 9 项进一步计算了无发病率的 DALY。该审查表明,目前代表结核病重要方面的方法存在方法学差距,包括结核病-人类免疫缺陷病毒合并感染、治疗、耐药性、肺外结核病和心理影响。我们提出了一套最佳实践建议。
需要在应用、敏感性测试和报告结核病残疾权重方面加强严谨性。此外,研究人员似乎渴望反映 GBD 残疾权重允许的范围之外的结核病体验元素。